HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
Males or females aged 18 years or older (≥18 years).
Patients diagnosed with pathologically confirmed advanced solid tumors.
Subjects have at least one target lesion as assessed per the RECIST 1.1.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.
Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;
Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies;
Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
Presence of Grade ≥ 2 toxicities as per Common Terminology Criteria for Adverse Events due to prior anti-tumor therapy.
7
Treatment groupsSee each treatment group below.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lead sponsor